Mangostanol

Mangostanol: A Comprehensive Encyclopedic Reference

1. Identity: Botanical and Chemical Characterization

1.1 Source Plant

Mangostanol is a naturally occurring phytochemical isolated from Garcinia mangostana L. (commonly known as mangosteen), a tropical evergreen tree belonging to the family Clusiaceae (synonym Guttiferae). Mangosteen is a tropical tree native to Southeast Asia that produces a fruit whose pericarp contains a family of tricyclic isoprenylated polyphenols referred to as xanthones. The tree is presumed to have originated in Southeast Asia or Indonesia and has largely remained indigenous to the Malay Peninsula, Myanmar, Thailand, Cambodia, Vietnam, and the Moluccas. The mangosteen tree is native to India, Myanmar, Malaysia, the Philippines, Sri Lanka, and Thailand, reaching 6–25 m in height with leathery, glabrous leaves; it is slow to grow.

It is referred to as the "queen of fruits" in Thailand, a country of origin. The edible portion of the fruit comprises only about 25% of the total volume, whereas the remainder is tough, bitter pericarp which exudes a yellow resin — hence the term xanthones, meaning "yellow" in Greek.

1.2 Chemical Identity of Mangostanol

During studies for identification of biologically active components from natural sources, a new polyoxygenated xanthone, mangostanol, was isolated from the fruit hull of Garcinia mangostana, along with known xanthones, α-mangostin, γ-mangostin, gartanin, 8-deoxygartanin, garcinone E, and related compounds.

Spectroscopic analysis, mainly by 1D and 2D NMR spectroscopy, established the structure of mangostanol as 3,5,9-trihydroxy-2,2-dimethyl-8-methoxy-7-(3-methylbut-2-enyl)-2H,6H-3,4-dihydropyrano[3,2-b]xanthen-6-one. This systematic IUPAC name reflects the compound's core xanthone scaffold modified with a saturated dihydropyrano ring — the key structural feature distinguishing mangostanol from the better-known but closely related α-mangostin and γ-mangostin.

Mangostanol is therefore classified as a prenylated xanthone — specifically, a dihydropyranoxanthone — consistent with the dominant phytochemical class found in mangosteen. Wikidata's chemical record for mangostin lists Mangostanol, a prenyl xanthone from Garcinia mangostana, as a documented entry in the phytochemical literature of the plant.

Mangostanol is listed among the xanthone-class compounds identified from Garcinia mangostana, alongside p-mangostin, 9-hydroxycalabaxanthone, mangostenone, allanxanthone E, mangostingone, garcinone D, and other prenylated xanthones.

1.3 Relationship to Other Mangosteen Xanthones

Over 50 distinct xanthone structures have been identified in the mangosteen pericarp, with alpha-mangostin and gamma-mangostin being the most studied. Mangostanol is among the minor xanthones of G. mangostana. α-Mangostin (1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one) is the most abundant polyphenolic xanthone in the mangosteen fruit. Mangostanol differs from α-mangostin primarily in possessing a partially saturated dihydropyrano ring in place of one of α-mangostin's open prenyl chains, giving mangostanol a more cyclized, compact molecular framework.

Alpha-mangostin (α-MG) and gamma-mangostin (γ-MG) are the most common xanthones in mangosteen fruits, although there are also beta-mangostin (β-MG), gartanin, and other xanthones in mangosteen. The mangosteen contains several chemical compound classes, including xanthones, benzophenones, flavonoids, and anthocyanins.

1.4 Plant Part Distribution and Concentration

Mangostanol was specifically isolated from the fruit hull (pericarp) of G. mangostana. The total xanthone content in G. mangostana is in the following order: pericarp > calyx > bark > stalk > stem > leaves > aril. The total xanthone content of the pericarp is 100 times higher than the aril. This strong concentration in the pericarp explains why mangostanol and other xanthones are predominantly sourced from pericarp extracts rather than the edible fruit pulp. HPLC analysis showed that α-mangostin contained about 30% w/w of crude ethanol extract of mangosteen pericarp.

2. Natural Sources, Forms, and Preparations

2.1 Natural Source and Extraction

The pericarp of mangosteen (Garcinia mangostana L.) fruit is a rich source of xanthones, which are bioactive compounds known for their antioxidant, anti-inflammatory, antimicrobial, and anticancer properties. Because mangostanol co-occurs with the major xanthones in the pericarp, commercial preparations of mangosteen that are standardized to xanthone content will contain mangostanol as a minor constituent alongside α-mangostin and γ-mangostin.

Particular emphasis has been put on mangosteen's rich content of prenylated and oxygenated xanthones, a class of polyphenols which is only synthesised within a small group of higher plants, fungi and lichens. Mangostanol, as one of these prenylated xanthones, is therefore a rare compound with limited natural distribution beyond the Garcinia genus and closely related plant families.

2.2 Commercial and Supplement Preparations

Mangosteen (Garcinia mangostana L., Clusiaceae) is a popular botanical dietary supplement in the United States, where it is used principally as an antioxidant. Commercial preparations in which mangostanol is naturally present as a minor constituent include:

• Whole-fruit juice beverages: Nutraceutical compositions uniquely provide natural xanthone compounds through the combination of the pulp and pericarp of the mangosteen fruit, along with selected juice and other phytochemical ingredients.
• Standardized pericarp extracts: Capsule or powder forms of dried pericarp extract, often standardized to a specified percentage of total xanthones (e.g., 10% xanthones by HPLC). These contain the full complex of pericarp xanthones including mangostanol.
• Xanthone-enriched fractions: Ethyl acetate as a green solvent exhibited the highest concentration of α-mangostin, followed by dichloromethane, ethanol, and water in optimized extraction processes.
• Fruit powder: Dried and ground pericarp powder, containing the natural mixture of xanthones in their native proportions.

Whereas mangosteen products containing puree from the entire fruit of Garcinia mangostana L. are considered novel food in the European Union, such products are widely used in the US due to their high antioxidant potential and traditional consumption in their countries of origin.

Because mangostanol itself is a minor xanthone, no commercially available preparations are currently standardized specifically to mangostanol content as an isolated ingredient. Rather, mangostanol is present as part of the broader xanthone profile in mangosteen-containing products. The isolation of pure mangostanol for research purposes requires chromatographic fractionation (e.g., silica gel column chromatography with n-hexane/ethyl acetate eluents) of crude pericarp extracts.

3. Traditional and Historical Use

3.1 Geographic and Cultural Context

For centuries, the mangosteen fruit has been used medically in Southeast Asia and is fast becoming a popular dietary supplement and juice beverage. The pericarp of mangosteen fruit has been used as a medicinal agent by Southeast Asians for centuries in the treatment of skin infections and wounds, as well as amoebic dysentery.

Garcinia mangostana L. (Clusiaceae) is a tropical tree native to Southeast Asia known as mangosteen, whose fruits possess a distinctive and pleasant taste. The seeds and pericarps of the fruit have a long history of use in the traditional medicinal practices of the region, and beverages containing mangosteen pulp and pericarps are sold worldwide as nutritional supplements.

3.2 Specific Traditional Applications

In folk medicine, mangosteen pericarp has been used to treat fever, convulsions, diarrhea, dysentery, stomach discomfort, trauma, pain, infected wounds, suppuration, and chronic ulcers. Mangosteen pericarp and the whole fruit have been used in Southeast Asia for centuries in the treatment of several diseases such as diarrhoea, dysentery, infections of the skin, mycosis, inflammation, cholera and fever.

Historically, this plant has been used for arthritis, dysentery, inflammation, skin disorders, and wounds. The fruit hull of G. mangostana has been used as a traditional medicine in Southeast Asia for the treatment of diarrhea, inflammation, and ulcers.

While mangostanol itself was only isolated and structurally characterized in the modern era, these traditional uses necessarily encompass the whole pericarp xanthone mixture, of which mangostanol forms a part. The pericarp preparations historically used would have contained mangostanol alongside the dominant α- and γ-mangostin compounds.

3.3 Traditional Preparation Methods

Traditional healers in countries such as Thailand, Malaysia, and Indonesia utilized various parts of the mangosteen fruit, particularly the rind (pericarp). The rind was often dried and ground into powders or brewed into decoctions to address a variety of ailments, including skin infections, diarrhea, dysentery, and wounds. These remedies were highly valued for their purported anti-inflammatory, antimicrobial, and wound-healing properties.

The rind has been used for internal and external infections, and poultices can be used to treat skin conditions; an extract of mangosteen pulp has even been used to control fever.

4. Key Constituents and Active Compounds of Garcinia mangostana

4.1 Phytochemical Profile

Current research indicates that mangosteen contains abundant chemical constituents, including polysaccharides, xanthones, procyanidins, benzophenones, bioflavonoids, and triterpenoids. Mangosteen contains phenolic acids, xanthones, prenylated benzophenone derivatives, flavonoids, anthocyanins, and condensed tannins. Furthermore, it has been hypothesized that the pericarp of the mangosteen is a rich source of oligomeric proanthocyanidins with B-type linkages.

The dominant bioactive compounds are the xanthones, a class of oxygenated heterocyclic polyphenols. Xanthones are the most abundant and the main bioactive component from mangosteen. The principal xanthones include:

• α-Mangostin — the most abundant and most-studied; a prenylated xanthone with two isoprenyl side chains and three hydroxyl groups.
• γ-Mangostin — the second most prominent; differs from α-mangostin by having a free phenolic hydroxyl instead of a methoxy group.
• β-Mangostin
• Gartanin and 8-deoxygartanin
• Garcinone E
• Mangostanol — a dihydropyranoxanthone (minor constituent, see Section 1)
• Additional minor prenylated xanthones: mangostanin, 9-hydroxycalabaxanthone, mangostenone, padiaxanthone, and others.

α-Mangostin is the major prenylated xanthone from Garcinia mangostana. Its structure is characterized by the presence of few functional groups amenable to chemical manipulations, but present in the molecule in multiple instances: three phenolic hydroxyl groups, two prenyl chains, and two unsubstituted aromatic carbons.

4.2 Structural Chemistry of Mangostanol in Context

Spectroscopic analysis established the structure of mangostanol as 3,5,9-trihydroxy-2,2-dimethyl-8-methoxy-7-(3-methylbut-2-enyl)-2H,6H-3,4-dihydropyrano[3,2-b]xanthen-6-one. The saturated dihydropyrano ring in mangostanol represents a cyclization product of a prenyl group, a structural motif that is part of the chemical diversity within the mangosteen xanthone family. Prenylated xanthone structures possess poor solubility in water but are soluble in organic solvents such as ethanol, methanol, and dimethyl sulfoxide (DMSO). This hydrophobicity is a property shared by mangostanol and most prenylated xanthones from the fruit hull.

5. Mechanisms of Action

5.1 Cyclic AMP Phosphodiesterase Inhibition

The pharmacological activity established most directly for mangostanol in primary literature is inhibition of cyclic AMP (cAMP) phosphodiesterase. Mangostanol, and α- and γ-mangostin show moderate inhibitory effects on cAMP phosphodiesterase. cAMP phosphodiesterase (PDE) is the enzyme responsible for hydrolyzing intracellular cyclic AMP to 5′-AMP, thereby terminating cAMP-mediated cell signaling. Phosphodiesterase inhibitors are pharmacological agents that enhance cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP) signaling by reducing the degradation of these cyclic nucleotides within cells. Both cAMP and cGMP are essential second messengers that relay and amplify incoming signals at cell surface receptors, making them critical components in signal transduction cascades and cellular signaling processes. The cAMP PDE inhibitory effect observed with mangostanol in the original isolation study is moderate rather than potent, and has only been described in the context of the biochemical characterization of the isolated compound.

5.2 Anti-inflammatory Mechanisms (Xanthone Class)

Because mangostanol has not been individually evaluated in detailed mechanistic studies to the same depth as α-mangostin and γ-mangostin, the mechanistic understanding of mangostanol's anti-inflammatory properties is necessarily placed within the context of the broader xanthone class from which it derives. Literature on α-mangostin consolidates mechanisms including the suppression of pro-inflammatory cytokines, modulation of immune cell activity, and inhibition of key signaling pathways such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK).

More specifically for the xanthone class: In C6 rat glioma cells, the xanthone γ-mangostin potently inhibited prostaglandin E2 release and competitively inhibited the activities of cyclooxygenase 1 (COX-1) and COX-2 enzymes, which are major mediators in regulating inflammation. γ-Mangostin also inhibited inhibitor kappa B kinase activity associated with expression of the COX-2 enzyme.

α-Mangostin has been found to inhibit the production of PGE2 and nitric oxide, and iNOS protein expression. TNF-α and IL-6 cytokines were inhibited significantly at 8 and 14 μg/mL concentrations. At higher doses, α-mangostin inhibits the translocation of NF-κB together with suppressing COX-2 enzymes, but not COX-1.

Pretreating intestinal epithelial cells with α-mangostin at 2.5, 5, and 10 μM caused a dose-dependent decrease in LPS-induced cytokines NO, PGE2, IL-6, TNFα, and IL-1β. It also dose-dependently inhibited LPS-induced mRNA expressions of iNOS, COX-2, IL-6, TNFα, IL-1β, and the innate immunity receptor TLR4 and adaptor protein MYD88. These results suggest that α-mangostin suppresses pro-inflammatory cytokine release through inhibiting the activation of TLR4-mediated TAK1-NF-κB signaling pathways.

A 2025 review consolidates the existing literature indicating that α-mangostin exerts anti-inflammatory effects including the suppression of pro-inflammatory cytokines, modulation of immune cell activity, and inhibition of key signaling pathways such as NF-κB and MAPK. Additionally, α-mangostin exhibits immunomodulatory properties by influencing both innate and adaptive immune responses, affecting macrophage polarization, T cell differentiation, and cytokine production.

5.3 Antioxidant Mechanisms

There is now very good evidence that α- and γ-mangostins are potent antioxidants in standard bioassays. Mangosteen extracts and xanthones from mangosteen were reported to scavenge DPPH, ABTS, and peroxynitrite radicals. The antioxidant activity of xanthones is attributed to their polyphenolic hydroxyl groups, which are capable of donating hydrogen atoms to reactive oxygen species and stabilizing the resulting radical via resonance delocalization across the aromatic ring system.

5.4 Enzyme Modulation

Some of the xanthones from mangosteen have been found to influence specific enzyme activities, such as aromatase, HIV-1 protease, inhibitor κB kinase, quinone reductase, sphingomyelinase, topoisomerase and several protein kinases, and they also modulate histamine H1 and 5-hydroxytryptamine2A receptor binding. These targets have been studied predominantly for α-mangostin and γ-mangostin. Direct demonstration of mangostanol's activity against these targets, beyond the cAMP phosphodiesterase inhibition described in its isolation paper, has not been established in the independently reviewed literature.

5.5 Anticancer Mechanisms

Mangosteen pericarp xanthones have been shown to inhibit several molecular targets in cell signaling cascades involving kinases, cyclooxygenases, and caspases. They have been proposed as potential chemopreventive agents for their ability to arrest the cell cycle, suppress tumor cell proliferation, induce apoptosis, and inhibit adhesion, invasion, and metastasis.

α-Mangostin (CAS number: 6147-11-1) has been reported to inhibit nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) in animal models and downregulate mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) signaling pathways.

5.6 Cholinesterase Inhibition

Methanol extracts of the pericarp and calyx of mangosteen demonstrated the most potent inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.90 and 0.37 µg/mL respectively. Statistical analysis showed a strong correlation between xanthone content and cholinesterase inhibition, with α-mangostin and γ-mangostin of pericarp as the key metabolites contributing to cholinesterase inhibition. Mangostanol's individual contribution to cholinesterase inhibition has not been separately quantified.

6. Scientific Evidence by Area of Use

Important framing note: Mangostanol as an isolated compound has been directly evaluated only for cAMP phosphodiesterase inhibitory activity in the original isolation study. All other biological activities discussed below are supported by evidence for the broader Garcinia mangostana xanthone fraction, standardized extracts, or the co-isolated major xanthones (α-mangostin, γ-mangostin), not for mangostanol individually. The overall state of evidence for mangosteen-derived xanthones in human health is summarized by the observation that despite consistently impressive preclinical findings across anticancer, neuroprotective, antidiabetic, and anti-inflammatory research, almost no well-designed clinical trials have confirmed therapeutic benefits for any condition in humans.

6.1 Antioxidant Activity

In vitro evidence (strong): Numerous in vitro studies have shown that mangosteen xanthones possess antioxidant, anti-proliferative, pro-apoptotic, anti-inflammatory and anti-carcinogenic activities. Xanthones consistently demonstrate free radical scavenging in DPPH, ABTS, and peroxynitrite assays.

Human clinical evidence (limited): One study investigated the absorption and antioxidant effects of a xanthone-rich mangosteen liquid in healthy human volunteers after the acute consumption of 59 mL of the supplement. The liquid contained mangosteen, aloe vera, green tea, and multivitamins. Results indicated that α-mangostin and vitamins B2 and B5 were bioavailable, with observed C_max at t_max of around 1 hour. This was a randomized, double-blind, placebo-controlled clinical trial, though the multi-ingredient formulation limits conclusions about mangosteen xanthones specifically.

A randomized, double-blind, placebo-controlled clinical trial was conducted using 60 participants (30 men and 30 women, ages 18–60) randomly divided into placebo and mangosteen groups. The trial duration was 30 days. ORAC was measured as an antioxidant biomarker. After the 30-day trial, the group given the mangosteen-based drink formula showed 15% more antioxidant capacity in the bloodstream than the placebo group. The same trial found that the C-reactive protein level significantly decreased by 46% in the mangosteen group between pre-intervention and post-intervention, while no significant decreases for the same biomarker were observed in the placebo group.

Limitations: The human antioxidant evidence comes from small trials using multi-ingredient or whole-extract preparations. No trial has studied mangostanol alone as an isolated antioxidant in humans.

6.2 Anti-inflammatory Effects

In vitro and animal evidence: The major secondary metabolites of mangosteen, the xanthones, exhibit a variety of biological activities including antibacterial, antifungal, anti-inflammatory, antioxidant, antiplasmodial, cytotoxic, and potential cancer chemopreventive activities.

In studies of induced paw edema or asthma in rodents, positive findings were observed with mangosteen xanthones. α-Mangostin inhibited total leukocyte migration, predominantly neutrophils, in vivo, and the levels of TNFα and IL-1β were significantly reduced in peritoneal fluids as measured by ELISA analysis. Taken together, these results demonstrate that α-mangostin acts well as an anti-inflammatory agent via inhibiting the hallmark mechanisms of inflammation.

Human evidence: Mangosteen juice has been evaluated for its effect on biomarkers of inflammation, with reduced C-reactive protein reported in individuals with body mass index 30 to 45 kg/m². The 30-day randomized trial of a mangosteen-based drink in 60 participants (Section 6.1) similarly demonstrated significant reduction in CRP. A randomized clinical trial using local delivery of 4% mangostana gel into the periodontal pockets of chronic periodontitis patients showed significant improvement in periodontal parameters.

Strength of evidence: Moderate for anti-inflammatory biomarker effects in small clinical trials; strong at the in vitro and animal level. No clinical trial has isolated mangostanol as the operative agent.

6.3 Anticancer Activity

In vitro evidence (extensive): Chemopreventive properties of mangosteen xanthones against specific human cancer cell lines have been demonstrated, including: alpha-mangostin in leukemia, breast, gastric, and pancreatic cancer cells; gartanin in urinary bladder cancer; gamma-mangostin and garcinone E in liver cancer cells.

One group demonstrated the potent cytotoxicity of three xanthones (α-mangostin, γ-mangostin, and 8-deoxygartanin) isolated from mangosteen pericarp against human melanoma SK-MEL-28 cells. Among these, α-mangostin showed the strongest activity. The effect of the three xanthones was associated with cell cycle arrest in G1 and induction of apoptosis via caspase 3 activation and mitochondrial membrane disruption.

Alpha-mangostin could effectively suppress fatty acid synthase (FAS) expression and inhibit intracellular FAS activity, resulting in decrease of intracellular fatty acid accumulation. It could also reduce cell viability and induce apoptosis in human breast cancer cells, increasing levels of the PARP cleavage product and attenuating the balance between anti-apoptotic and pro-apoptotic proteins of the Bcl-2 family.

For mangostanol specifically, a new prenylxanthone, garcimangostanol, was isolated from the EtOAc-soluble partition of the ethanol extract of the pericarp of Garcinia mangostana L. Compounds from the pericarp exhibited either significant or moderate cytotoxicity against MCF-7, A549, Hep-G2, and CNE human cancer cell lines. Note that "garcimangostanol" referenced here is a distinct compound isolated by Fu et al. (2013), not the same as "mangostanol" (Chairungsrilerd et al., 1996), despite the similarity of names.

Studies have shown cytotoxicity of the mangosteen xanthone derivatives against several cancer cell lines, and it is of interest to note that gambogic acid, a prenylated xanthone from Garcinia hanburyi, a closely related species, is in phase I clinical trials as an anticancer agent in the People's Republic of China.

Human clinical evidence: There are no published human clinical trials evaluating mangostanol or mangosteen xanthone extracts for cancer treatment. Evidence remains at the in vitro and animal stages.

6.4 Antimicrobial Activity

Garcinia mangostana improves the antioxidant activity of plasma in humans and has anti-inflammatory activity. Beyond this, the antimicrobial activity of mangosteen xanthones has been documented in vitro. The xanthone class as a whole exhibits activity against a range of pathogens.

These components were proven to generate beneficial human health conditions through various pharmacological activities such as antioxidant, anti-acne, anti-aging, anti-hyperpigmentation, antibacterial, antidiabetic, anti-obesity, anti-inflammatory, antimalarial, antiparasitic, and antitumor activities.

Strength of evidence: Primarily in vitro; no human trials for antimicrobial use of mangostanol specifically.

6.5 Neuroprotective and Cognitive Effects

Nonmetric multidimensional scaling analysis revealed α-mangostin and γ-mangostin of pericarp as the key metabolites contributing to cholinesterase inhibition. Due to the increasing demand of mangosteen products, repurposing of fruit waste (pericarp) has great potential for enhancement of the cognitive health of human beings.

Chemical compounds isolated from mangosteen have shown advantageous outcomes for multiple pathological conditions including Alzheimer's disease, various cancers, bipolar disorder, schizophrenia, neuropathic pain, chronic kidney disease, and pulmonary fibrosis. These findings are predominantly from in vitro and preclinical animal studies; controlled human trials are lacking.

6.6 Antidiabetic and Metabolic Effects

Mangosteen pericarp extract demonstrated significant inhibitory activity against α-glucosidase and acetylcholinesterase (AChE), with IC50 values of 31.02 and 70.56 µg/mL, respectively. Inhibition of α-glucosidase is a mechanism relevant to blood glucose management (analogous to acarbose's mechanism of action). These findings are from in vitro models; no human clinical trials targeting diabetes specifically with mangostanol have been published.

6.7 Periodontal and Oral Health

Xanthones have been shown to exhibit various pharmacological properties, including antioxidant, antimicrobial, anti-carcinogenic, and anti-allergic properties. In particular, α-mangostin compounds exhibit anti-inflammatory activity by inhibiting the production of nitrous oxide, TNF-α, and interleukin-8. A randomized clinical trial using local delivery of 4% mangostana gel into the periodontal pockets of chronic periodontitis patients showed significant improvement in periodontal parameters. This represents one of the more directly applicable human-level clinical findings in the mangosteen xanthone literature, though again this is for the extract formulation, not isolated mangostanol.

7. Body Systems and Health Areas Associated with Mangostanol and Co-occurring Xanthones

Based on the reviewed scientific and traditional evidence, Garcinia mangostana xanthones — of which mangostanol is a constituent — have been investigated or used in relation to the following body systems:

• Immune system: The pharmacological effects of mangosteen include anti-oxidative, anti-inflammatory, anti-tumor, anti-depressive, anti-microbial, anti-parasitic, and neuroprotective effects.
• Gastrointestinal system: Traditional use for diarrhea, dysentery, stomach ulcers, and abdominal pain; in vitro evidence for anti-inflammatory effects in intestinal epithelial cells.
• Integumentary system (skin): Traditional use for infected wounds, skin infections, and chronic ulcers; it has also been used in the treatment of various skin conditions.
• Cardiovascular system: Xanthones possess anti-inflammatory properties such as COX inhibition and have cardiovascular protective effects. Antioxidant reduction of LDL oxidation has been shown in vitro.
• Nervous system: Cholinesterase inhibition relevant to cognitive function; neuroprotective effects observed in cell models.
• Metabolic system: α-Glucosidase inhibition in vitro suggesting potential relevance to blood glucose regulation.
• Oral cavity: Antimicrobial and anti-inflammatory activity relevant to periodontal disease, with one positive randomized clinical trial of a mangosteen gel formulation.
• Oncology (preclinical): Extensive in vitro cytotoxicity data across multiple cancer cell types; no clinical trials.

8. Pharmacokinetics and Bioavailability

α-Mangostin is comprised of a tricyclic aromatic ring system and a mixture of hydroxyl and isoprenyl groups, making it extremely hydrophobic. This physicochemical property, shared by mangostanol and other prenylated xanthones, creates significant bioavailability challenges.

Pharmacokinetic studies in rats demonstrated low systemic bioavailability of α-mangostin following oral dosing, with extensive metabolism to conjugated metabolites. A small human study with mangosteen juice detected α-mangostin and its phase II metabolites in plasma, confirming at least partial absorption. Evidence of Phase II metabolism has been demonstrated using multiple reaction monitoring (MRM) to identify at least 2 mono-glucuronides and 2 bi-glucuronides. No pharmacokinetic data specific to mangostanol in humans or animals has been identified in the reviewed literature.

9. Dosage Forms and Reported Dosages

No clinical dosing data for isolated mangostanol has been identified in the peer-reviewed or regulated literature. Dosage information in the following refers to mangosteen preparations (extracts or juice) that contain the full xanthone profile, including mangostanol:

• Mangosteen juice / multi-ingredient beverage: One clinical study investigated the antioxidant effects of a xanthone-rich mangosteen liquid in healthy human volunteers after the acute consumption of 59 mL of the supplement.
• Mangosteen-based drink (30-day trial): A randomized, double-blind, placebo-controlled clinical trial was conducted using 60 participants (30 men and 30 women, ages 18–60). The study's specific daily dose volume was not reported in available abstracts, but the intervention was a mangosteen-based beverage consumed daily for 30 days.
• Periodontal gel: A randomized clinical trial used local delivery of a 4% mangostana gel into the periodontal pockets of chronic periodontitis patients.

Because mangostanol itself is only a minor constituent of whole-pericarp preparations, its dose in any of the above studies is not quantified. There are no established or regulatory-approved dosing guidelines for mangostanol as a standalone ingredient.

10. Safety Considerations and Interactions

10.1 General Tolerability

In the 30-day mangosteen beverage trial, the effects on hepatic function (aspartate aminotransferase and alanine aminotransferase) and kidney function (creatinine) were investigated, and results indicated that after the 30-day consumption of the beverage, there were no adverse changes in these markers.

10.2 Lactic Acidosis (Case Report)

A clinically significant safety signal has been described in a published case report. A case report described severe lactic acidosis following consumption of mangosteen juice daily for 12 months. A study published in the American Journal of Kidney Diseases highlighted a case of severe lactic acidosis linked to consuming mangosteen juice as a dietary supplement. This case involved prolonged, high-dose daily consumption of a concentrated mangosteen juice product, not the moderate consumption of fresh fruit. Alpha-mangostin, a xanthone, could stimulate apoptosis in leukaemia cells in vitro, and a possible adverse effect may occur from chronic consumption of mangosteen juice containing xanthones.

10.3 Anticoagulant Interactions

The xanthone compounds in the fruit have been shown to slow the process of blood clotting. This effect can be dangerous for people taking blood-thinning medications (anticoagulants), as mangosteen could increase the risk of bruising and bleeding.

10.4 Cytochrome P450 Drug Interactions

Mangosteen may increase the risk of side effects of cytochrome P450 substrate drugs, though clinical relevance is not known. Inhibition or induction of CYP enzymes by mangosteen xanthones would have implications for any drugs metabolized by those pathways.

10.5 Potential Interference with Cancer Treatment

Some research shows that these supplements may interfere with cancer treatment and adversely affect blood sugar levels. Alpha-mangostin exacerbated symptoms of experimental colitis in a mice model, though clinical relevance is not known.

10.6 European Union Novel Food Status

Mangosteen products containing puree from the entire fruit of Garcinia mangostana L. are considered novel food in the European Union, which means they require safety authorization before being placed on the EU market. This regulatory classification reflects the limited long-term human safety data available for concentrated mangosteen preparations.

10.7 Regulatory Context in the United States

The fruit juice made of mangosteen has become a major botanical dietary supplement, and was ranked as one of the top-selling "botanicals" in the food, beverage and supplement market. In the U.S., mangosteen-derived supplements are regulated as dietary supplements under DSHEA and are not evaluated by the FDA for safety or efficacy prior to marketing.

11. Summary of Evidence Strength

The following summarizes the state of evidence for mangostanol and mangosteen xanthones across key areas:

• cAMP phosphodiesterase inhibition (mangostanol specifically): Demonstrated in vitro at moderate level in the original isolation study; not replicated in independent mechanistic studies.
• Antioxidant activity (xanthone extract): Strong in vitro; confirmed in small human trials with multi-ingredient or whole-extract preparations.
• Anti-inflammatory activity: Strong mechanistic evidence in vitro and in animal models; limited human clinical support from small RCTs using extracts.
• Anticancer activity: Extensive in vitro cytotoxicity data; no human clinical trials; preclinical stage only.
• Antimicrobial activity: Demonstrated in vitro across bacterial and fungal pathogens; no human trial data.
• Cognitive/neuroprotective effects: Preliminary in vitro and animal data; no human RCTs.
• Antidiabetic effects: In vitro enzyme inhibition data; no human clinical evidence.
• Oral health: One positive RCT for a periodontal gel formulation.

Sales of mangosteen-containing beverages in the USA alone exceeded $200 million in 2008 despite very limited animal and human studies. This commercial development has significantly outpaced the clinical evidence base, particularly for mangostanol as an isolated, characterized compound.

References

• Chairungsrilerd N et al. "Mangostanol, a prenyl xanthone from Garcinia mangostana." Phytochemistry, 1996. ScienceDirect.
• Chin YW, Kinghorn AD. "Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement." PMC / Mini Rev Org Chem, 2008.
• Gutierrez-Orozco F, Failla ML. "Biological Activities and Bioavailability of Mangosteen Xanthones: A Critical Review of the Current Evidence." PMC / Nutrients, 2013.
• Zhang W et al. "Botanical characteristics, chemical components, biological activity, and potential applications of mangosteen." PMC / PeerJ, 2023.
• Franceschinis L et al. "Pharmacokinetic characterization of mangosteen (Garcinia mangostana) fruit extract standardized to α-mangostin in C57BL/6 mice." PMC, 2018.
• Aizat WM et al. "Recent updates on metabolite composition and medicinal benefits of mangosteen plant." PMC / PeerJ, 2019.
• Emami SA et al. "Antidotal and protective effects of mangosteen (Garcinia mangostana) against natural and chemical toxicities: A review." PMC, 2023.
• Akao Y et al. "Anti-Cancer Effects of Xanthones from Pericarps of Mangosteen." PMC / Int J Mol Sci, 2008.
• Xie Z et al. "Daily consumption of a mangosteen-based drink improves in vivo antioxidant and anti-inflammatory biomarkers in healthy adults: a randomized, double-blind, placebo-controlled clinical trial." PMC / Food Sci Nutr, 2015.
• Kondo M et al. "Bioavailability and Antioxidant Effects of a Xanthone-Rich Mangosteen (Garcinia mangostana) Product in Humans." J Agric Food Chem, 2009.
• Barreto MCS et al. "An anti-inflammatory molecular mechanism of action of α-mangostin, the major xanthone from the pericarp of Garcinia mangostana." PubMed, 2018.
• Alzahrani A et al. "α-Mangostin Is a Xanthone Derivative from Mangosteen with Potent Immunomodulatory and Anti-Inflammatory Properties." PMC / Biomolecules, 2025.
• Al-Rawi N et al. "α-Mangostin: A Xanthone Derivative in Mangosteen with Potent Anti-Cancer Properties." PMC, 2024.
• Jia L et al. "Alpha-mangostin inhibits intracellular fatty acid synthase and induces apoptosis in breast cancer cells." PMC, 2014.
• Farizal J, Hamidon H. "Two New Chemical Constituents from the Stem Bark of Garcinia mangostana." PMC / Molecules, 2014.
• Xu Y et al. "Xanthones from the Pericarp of Garcinia mangostana." PMC / Molecules, 2017.
• Shan T et al. "Cytotoxic Prenylated Xanthones from the Pericarps of Garcinia mangostana." PMC / Molecules, 2014.
• Khaw KY et al. "LC-QTOF-MS analysis of xanthone content in different parts of Garcinia mangostana and its influence on cholinesterase inhibition." PMC, 2020.
• Wichit P et al. "Clinical and Immunological Efficacy of Mangosteen and Propolis Extracted Complex in Patients with Gingivitis: A Multi-Centered Randomized Controlled Clinical Trial." PMC, 2021.
• Fu M et al. "A New Xanthone from the Pericarp of Garcinia mangostana." Natural Product Communications, 2013.
• Memorial Sloan Kettering Cancer Center — Integrative Medicine: Mangosteen.
• Wong LP, Klemmer PJ. "Severe Lactic Acidosis Associated With Juice of the Mangosteen Fruit Garcinia mangostana." Am J Kidney Dis, 2008.
• Tran TH et al. "Comparative metabolomics of acetylcholinesterase and α-glucosidase inhibitors in pericarp of Garcinia mangostana L." PMC, 2025.
• Ciochina R, Grossman RB. "Chemistry of α-mangostin. Studies on the semisynthesis of minor xanthones from Garcinia mangostana." PubMed, 2014.
• Kurose H et al. "Altered mRNA Expression Related to the Apoptotic Effect of Three Xanthones on Human Melanoma SK-MEL-28 Cell Line." PMC, 2013.
• Wischhusen J et al. "Prenylated xanthones from mangosteen (Garcinia mangostana) target oxidative mitochondrial respiration in cancer cells." ScienceDirect / Biomedicine & Pharmacotherapy, 2024.